Journal of Hebei University(Natural Science Edition) >

2025 , Vol. 45 >Issue 4: 378 - 388

DOI: https://doi.org/10.3969/j.issn.1000-1565.2025.04.006

Research progress on application, preparation process and quality standard of cerebroprotein hydrolysates

  • TAN Zhilei ,
  • GENG Xue ,
  • SHENG Zihan ,
  • JIN Xingyu ,
  • XU Feng ,
  • LI Jinhong
Expand
  • 1. State Key Laboratory of Food Nutrition and Safety, College of Bioengineering, Tianjin University of Science and Technology, Tianjin 300457, China; 2. Hebei Zhitong Biopharmaceutical Co., Ltd., Baoding 072656, China; 3. Hebei Province Animal Derived Peptide Biochemical Drug Technology Innovation Center, Baoding 072656, China

Received date: 2024-10-17

  Online published: 2025-07-11

Fold

Abstract

Cerebroprotein hydrolysate is a mixture of polypeptides and amino acids obtained from porcine brain after enzymatic hydrolysis and filtration. Cerebroprotein hydrolysate can exert neurotrophic activity on neurons in the peripheral or central nervous system, and has a good effect in the adjuvant treatment of various neurodegenerative diseases. This review mainly introduced the application, preparation process and quality standards of cerebroprotein hydrolysate, which provided a reference for further improving the production process of cerebroprotein hydrolysate and developing new oral products.

Key words： cerebroprotein hydrolysate; neurodegenerative diseases; delipidation; enzymatic hydrolysis

Cite this article

TAN Zhilei , GENG Xue , SHENG Zihan , JIN Xingyu , XU Feng , LI Jinhong . Research progress on application, preparation process and quality standard of cerebroprotein hydrolysates[J]. Journal of Hebei University(Natural Science Edition), 2025 , 45(4) : 378 -388 . DOI: 10.3969/j.issn.1000-1565.2025.04.006

References

[1] 赵浩林,孙世标,秦国燕,等.中药调控小胶质细胞极化平衡治疗神经退行性疾病的机制研究进展[J].中国实验方剂学杂志, 2024, 30(2): 244-253. DOI: 10.13422/j.cnki.syfjx.20232294.
[2] OU G Y, LIN W W, ZHAO W J. Neuregulins in neurodegenerative diseases[J]. Front Aging Neurosci, 2021, 13: 662474. DOI: 10.3389/fnagi.2021.662474.
[3] MARGHANI B H, REZK S, ATEYA A I, et al. The effect of cerebrolysin in an animal model of forebrain ischemic-reperfusion injury: new insights into the activation of the Keap1/Nrf2/antioxidant signaling pathway[J]. Int J Mol Sci, 2023, 24(15): 12080. DOI: 10.3390/ijms241512080.
[4] NAMBI P, SATHYAMOORTHY Y, KALIYAPPAN K, et al. Fucoidan(a sulfated polysaccharide)and cerebroprotein in combination alleviate the neuroinflammation-mediated neural damage and functional deficits in the focal cerebral ischemia model of rat[J]. Neuroscience, 2023, 524: 52-64. DOI: 10.1016/j.neuroscience.2023.05.003.
[5] GRGAC I, HERZER G, VOELCKEL W G, et al. Neuroprotective and neuroregenerative drugs after severe traumatic brain injury: a narrative review from a clinical perspective[J]. Wien Klin Wochenschr, 2024, 136(23/24): 662-673. DOI: 10.1007/s00508-024-02367-9.
[6] JAROSZ K, KOJDER K, SKONIECZNA-Z·YDECKA K, et al. The effects of neuromonitoring and cerebrolysin administration on outcomes in patients with traumatic brain injury-an interventional pilot study[J]. J Clin Med, 2024, 13(2): 353. DOI: 10.3390/jcm13020353.
[7] MOHAMED YUSOF N I S, MOHD FAUZI F. Nature’s toolbox for Alzheimer’s disease: a review on the potential of natural products as Alzheimer’s disease drugs[J]. Neurochem Int, 2024, 176: 105738. DOI: 10.1016/j.neuint.2024.105738.
[8] CHEN M X, SONG W, CHEN Z J, et al. Cerebroprotein hydrolysate attenuates neurodegenerative changes in Alzheimer’s mice model via ferroptosis pathway[J]. Front Pharmacol, 2023, 14: 1177503. DOI: 10.3389/fphar.2023.1177503.
[9] THARWAT E K, ABDELATY A O, ABDELRAHMAN A I, et al. Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson’s disease induced by reserpine[J]. Metab Brain Dis, 2023, 38(5): 1513-1529. DOI: 10.1007/s11011-023-01189-4.
[10] 中华医学会神经病学分会帕金森病及运动障碍学组.亨廷顿病的诊断与治疗指南[J].中华神经科杂志, 2011, 44(9):4.DOI:10.3760/cma.J.issn.1006-7876.2011.09.017.
[11] 周昱君,陈秋宇,孙卓,等.肌萎缩侧索硬化症发病机制及药物研究进展[J].中国药理学通报,2024,40(2):201-207.
[12] 李静静.不同类型的脊髓小脑性共济失调患者的临床特点和眼震电图特点的描述及相关性分析[D].南昌:南昌大学, 2023. DOI: 10.27232/d.cnki.gnchu.2023.000619.
[13] GUO H M, YANG H Z, DI C J, et al. Identification and validation of active ingredient in cerebrotein hydrolysate-I based on pharmacokinetic and pharmacodynamic studies[J]. Drug Metab Dispos, 2023,51(12): 1615-1627. DOI: 10.1124/dmd.123.001443.
[14] ZHU L, LIU Y J, WU X L, et al. Cerebroprotein hydrolysate-I protects senescence-induced by D-galactose in PC12 cells and mice[J]. Food Sci Nutr, 2021, 9(7):3722-3731. DOI: 10.1002/fsn3.2333.
[15] AVCI S, GUNAYDIN S, ARI N S, et al. Cerebrolysin alleviating effect on glutamate-mediated neuroinflammation via glutamate transporters and oxidative stress[J]. J Mol Neurosci, 2022, 72(11): 2292-2302. DOI: 10.1007/s12031-022-02078-8.
[16] 白恩侠,张卫柱.牛脑蛋白水解物工艺研究[J].经济动物学报, 2002, 6(3): 49-51. DOI: 10.13326/j.jea.2002.03.029.
[17] 常飞,杨雪果,肖士成,等.脱脂羊脑蛋白酶解条件优化及酶解产物体外抗氧化活性[J].食品科学, 2015, 36(3): 114-121. DOI: 10.7506/spkx1002-6630-201503022.
[18] 张晓頔,戴志远.鱼副产物蛋白水解物生物活性及应用研究进展[J].食品科学, 2021, 42(13): 335-343. DOI: 10.7506/spkx1002-6630-20200523-271.
[19] WU X L, LIU Y J, ZHU L, et al. Cerebroprotein hydrolysate-I inhibits hippocampal neuronal apoptosis by activating PI3K/Akt signaling pathway in vascular dementia mice[J]. Neuropsychiatr Dis Treat, 2021, 17: 2359-2368. DOI: 10.2147/NDT.S311760.
[20] VILLARREAL-REYNA G, GARZA-MORALES R, SOTO-DOMÍNGUEZ A, et al. Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation[J]. Eur J Med Res, 2022, 27(1): 257. DOI: 10.1186/s40001-022-00889-4.
[21] REN X, WEN Y, YUAN M, et al. Cerebroprotein hydrolysate-I ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via the p53/SAT1/ALOX15 signalling pathway[J]. Eur J Pharmacol, 2024, 979: 176820. DOI: 10.1016/j.ejphar.2024.176820.
[22] MAHMOUDI J, MAHMOODPOOR A, AMIRNIA M, et al. The induced decrease in TLR2 and TLR4 by cerebrolysin in the alcoholic liver of rats[J]. J Cell Physiol, 2019, 234(9): 16290-16294. DOI: 10.1002/jcp.28293.
[23] GAUTHIER S, PROAÑO J V, JIA J P, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials[J]. Dement Geriatr Cogn Disord, 2015, 39(5/6): 332-347. DOI:10.1159/000377672.
[24] 张彤彤,胡远卓.脑蛋白水解物制剂对脑神经类疾病保护作用的研究进展[J].世界临床药物, 2020, 41(9): 747-751. DOI: 10.13683/j.wph.2020.09.016.
[25] SENGOKU R. Aging and Alzheimer’s disease pathology[J]. Neuropathology, 2020, 40(1): 22-29. DOI:10.1111/neup.12626.
[26] SHARMA H S, MURESANU D F, CASTELLANI R J, et al. Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer’s disease[J]. Prog Brain Res, 2019, 245: 145-200. DOI: 10.1016/bs.pbr.2019.03.009.
[27] 薛欣怡,张翼,刘亚月.天然来源的乙酰胆碱酯酶抑制剂的筛选方法综述[J].天然产物研究与开发, 2021, 33(5): 892-897. DOI:10.16333/j.1001-6880.2021.5.021.
[28] SINGH A, ANSARI V A, MAHMOOD T, et al. Targeting abnormal tau phosphorylation for Alzheimer’s therapeutics[J]. Horm Metab Res, 2024, 56(7): 482-488. DOI:10.1055/a-2238-1384.
[29] 张涛,陈艳红,常高萍,等.基于乙酰胆碱酯酶和氧化应激研究海胆酮对阿尔茨海默症的作用机制[J].食品科学, 2022, 43(11): 105-112. DOI: 10.7506/spkx1002-6630-20210608-097.
[30] 史彩云.脑蛋白水解物对缺血性脑卒中小鼠的治疗作用及其调控内质网应激相关机制的研究[D].张家口:河北北方学院, 2023. DOI: 10.27767/d.cnki.ghbbf.2023.000454.
[31] 付东兴,刘俊彤,司函瑞,等.治疗阿尔茨海默症的天然药物研究进展[J].世界中医药, 2022, 17(2): 271-275. DOI: 10.3969/j.issn.1673-7202.2022.02.04
[32] FIANI B, COVARRUBIAS C, WONG A, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes[J]. Neurol Sci, 2021, 42(4): 1345-1353. DOI: 10.1007/s10072-021-05089-2.
[33] ROCKENSTEIN E, ADAME A, MANTE M, et al. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance[J]. J Neural Transm, 2003, 110(11): 1313-1327. DOI:10.1007/s00702-003-0025-7.
[34] ROCKENSTEIN E, DESPLATS P, UBHI K, et al. Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease[J]. Stem Cell Res, 2015, 15(1): 54-67. DOI: 10.1016/j.scr.2015.04.008.
[35] UBHI K, ROCKENSTEIN E, VAZQUEZ-ROQUE R, et al. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease[J]. J Neurosci Res, 2013, 91(2): 167-177. DOI: 10.1002/jnr.23142.
[36] GAVRILOVA S I, ALVAREZ A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use[J]. Med Res Rev, 2021, 41(5): 2775-2803. DOI: 10.1002/med.21722.
[37] 周环, 钟楚锋, 杨谕晨. 脑蛋白水解物联合丁苯酞治疗阿尔茨海默病的临床效果[J]. 中外医学研究, 2022, 20(16): 26-29. DOI: 10.14033/j.cnki.cfmr.2022.16.007.
[38] ARMSTRONG M J, OKUN M S. Diagnosis and treatment of parkinson disease: a review[J]. JAMA, 2020, 323(6): 548-560. DOI: 10.1001/jama.2019.22360.
[39] OZKIZILCIK A, SHARMA A, LAFUENTE J V, et al. Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson’s disease[J]. Prog Brain Res, 2019, 245: 201-246. DOI: 10.1016/bs.pbr.2019.03.014.
[40] 刘文萍,李静,彭颜晖,等.脑蛋白水解物注射液对老年帕金森患者的疗效分析[J].现代生物医学进展, 2017, 17(27): 5312-5314. DOI: 10.13241/j.cnki.pmb.2017.27.028.
[41] 阎锟,武筱林,刘英娟,等.脑蛋白水解物-Ⅰ对帕金森病小鼠肠道菌群的调节作用[J].解剖学报, 2023, 54(5): 497-504. DOI: 10.16098/j.issn.0529-1356.2023.05.001.
[42] 王陇德,刘建民,杨弋,等.我国脑卒中防治仍面临巨大挑战: 《中国脑卒中防治报告2018》概要[J].中国循环杂志, 2019, 34(2): 105-119. DOI: 10.3969/j.issn.1000-3614.2019.02.001.
[43] REN Y Q, MA X Q, WANG T T, et al. The cerebroprotein hydrolysate-I plays a neuroprotective effect on cerebral ischemic stroke by inhibiting MEK/ERK1/2 signaling pathway in rats[J]. Neuropsychiatr Dis Treat, 2021, 17: 2199-2208. DOI: 10.2147/NDT.S313807.
[44] MITROVIC' S Z, KONSTANTINOVIC' L M, MILER JERKOVIC'V, et al. Extended poststroke rehabilitation combined with cerebrolysin promotes upper limb motor recovery in early subacute phase of rehabilitation: a randomized clinical study[J]. Medicina, 2023, 59(2): 291. DOI: 10.3390/medicina59020291.
[45] BRAININ M. Cerebrolysin: a multi-target drug for recovery after stroke[J]. Expert Rev Neurother, 2018, 18(8): 681-687. DOI: 10.1080/14737175.2018.1500459.
[46] HEISS W D, BRAININ M, BORNSTEIN N M, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial[J]. Stroke, 2012, 43(3):630-636. DOI: 10.1161/STROKEAHA.111.628537.
[47] KHASANOVA D R, KALININ M N. Cerebrolysin as an early add-on to reperfusion therapy: risk of hemorrhagic transformation after ischemic stroke(CEREHETIS), a prospective, randomized, multicenter pilot study[J]. BMC Neurol, 2023, 23(1): 121. DOI: 10.1186/s12883-023-03159-w.
[48] AKAMATSU Y, HANAFY K A. Cell death and recovery in traumatic brain injury[J]. Neurotherapeutics, 2020, 17(2): 446-456. DOI: 10.1007/s13311-020-00840-7.
[49] MASLIAH E, DÍEZ-TEJEDOR E. The pharmacology of neurotrophic treatment with cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders[J]. Drugs Today, 2012, 48(Suppl A): 3-24. DOI: 10.1358/dot.2012.48(Suppl.A).1739716.
[50] SHARMA H S, ZIMMERMANN-MEINZINGEN S, JOHANSON C E. Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat[J]. Ann N Y Acad Sci, 2010, 1199(1): 125-137. DOI: 10.1111/j.1749-6632.2009.05329.x.
[51] ZHÀO H, LIU Y, ZENG J, et al. Troxerutin cerebroprotein hydrolysate injection ameliorates neurovascular injury induced by traumatic brain injury-via endothelial nitric oxide synthase pathway regulation[J]. Int J Neurosci, 2018, 128(12): 1118-1127. DOI:10.1080/00207454.2018.1486828.
[52] VERISEZAN ROSU O, JEMNA N, HAPCA E, et al. Cerebrolysin and repetitive transcranial magnetic stimulation(rTMS)in patients with traumatic brain injury: a three-arm randomized trial[J]. Front Neurosci, 2023, 17: 1186751. DOI:10.3389/fnins.2023.1186751.
[53] 卢文静,陈佳佳,谌迪,等.酶促水解制备猪脑抗氧化活性肽[J].浙江农业科学, 2022, 63(8): 1833-1836. DOI: 10.16178/j.issn.0528-9017.20212979.
[54] 余礼碧,施燕,王占利,等.脑蛋白粉的制备及其酶解方法的研究[J].氨基酸和生物资源, 2000, 22(3): 18-21. DOI: 10.14188/j.ajsh.2000.03.005.
[55] 冯小龙,李成胜,陈晓彦,等.一种具有改善记忆功能的用于口服的脑多肽组合物: CN108402473A[P]. 2018-08-17.
[56] 张鹏,朱永星,夏生跃,等.一种口服用脑蛋白水解物的制备工艺: CN112063677A[P]. 2020-12-11.
[57] 常飞,杨雪果,肖士成,等.脱脂羊脑蛋白酶解条件优化及酶解产物体外抗氧化活性[J].食品科学, 2015, 36(3): 114-121. DOI:10.7506/spkx1002-6630-201503022.
[58] 何来鹏,浦同骄,彭明嫒,等.一种可以营养脑神经、促进脑健康的脑多肽及其组合物: CN111869786A[P]. 2020-11-03.
[59] 张惠敏,王娅莉,耿亚鹏.猪脑蛋白水解物中小分子肽的制备及生物活性测定[J].河北医药, 2006, 28(3): 223-224. DOI: 10.3969/j.issn.1002-7386.2006.03.041.
[60] DAI L X, REICHERT C L, HINRICHS J, et al. An erosion-type hydrolysis behavior of insoluble protein fraction from Chlorella protothecoides[J]. J Sci Food Agric, 2020, 100(3): 1072-1079. DOI: 10.1002/jsfa.10112.
[61] KALAMBURA S, KRICKA T, KI D, et al. High-risk bio-waste processing by alkaline hydrolysis and isolation of amino acids[J]. Teh Vjesn, 2016, 23(6): 1771-1776. DOI:10.17559/tv-20150427225158.
[62] 马晓明,范俐妹,张泽军,等.酶水解降低牛奶蛋白致敏性研究进展[J].中国乳品工业, 2024, 52(7): 53-59. DOI: 10.19827/j.issn1001-2230.2024.07.008.
[63] 张伦,骆鑫鑫,王斌,等.南极磷虾活性肽的研究进展[J].浙江海洋大学学报(自然科学版), 2022, 41(2): 176-182. DOI: 10.3969/j.issn.1008-830X.2022.02.013.
[64] MORE K N, LIM T H, KANG J L, et al. A fluorogenic assay: analysis of chemical modification of lysine and arginine to control proteolytic activity of trypsin[J]. Molecules, 2021, 26(7): 1975. DOI: 10.3390/molecules26071975.
[65] ZHAO X O, ZHANG M N, MUHAMMAD I, et al. An antibacterial peptide with high resistance to trypsin obtained by substituting d-amino acids for trypsin cleavage sites[J]. Antibiotics, 2021, 10(12): 1465. DOI: 10.3390/antibiotics10121465.
[66] 王宏伟.脑酶水解物制药工艺的改进[D].哈尔滨:东北林业大学, 2004.
[67] 黄洁,王孝功,单敏,等.脑蛋白水解物的提取工艺优化[J].中国药房, 2016, 27(28): 3985-3987.
[68] 靳颖华.脑蛋白水解物注射液制备工艺的初步研究[J].中国医药导刊, 2015, 17(11): 1182. (
Options
Outlines

/

〈 〉